Sign in Subscribe
Stock offerings

Savara Inc. Announces Pricing of $130 Million Underwritten Public Offering

Strategic Insights

— 1 min read

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, has announced the pricing of an underwritten public offering of 23,809,524 shares of its common stock. The offering, which will close on October 31, 2025, subject to customary closing conditions, is expected to raise $130 million in gross proceeds. The company plans to use the proceeds from the offering for general corporate purposes, including funding clinical development and pursuing regulatory approval for its lead program, MOLBREEVI*.

Key Takeaways:

  • Savara Inc. has priced an underwritten public offering of 23,809,524 shares of its common stock at a price of $4.20 per share, raising $130 million in gross proceeds.
  • The offering is being led by joint book-running managers Jefferies, Piper Sandler, and Guggenheim Securities, with Oppenheimer & Co. as the lead manager.
  • Savara plans to use the proceeds from the offering for general corporate purposes, including funding clinical development and pursuing regulatory approval for MOLBREEVI*.
  • The offering is expected to close on October 31, 2025, subject to customary closing conditions.
  • MOLBREEVI* is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
  • Savara's management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

Statistics:

  • 23,809,524 shares of common stock will be sold in the offering.
  • The price per share is $4.20.
  • Gross proceeds from the offering are $130,000,000.
  • The underwriters have an option to purchase an additional 4,642,857 shares of common stock.
  • The company plans to use the proceeds for general corporate purposes, including funding clinical development and pursuing regulatory approval for MOLBREEVI*.

Sources:

  • Savara Inc.'s press release dated October 29, 2025.
  • Business Wire: Savara Announces Pricing of $130 Million Underwritten Public Offering
  • Savara's existing shelf registration statement filed with the Securities and Exchange Commission (SEC) on May 9, 2024.

Read more